
Related Practices

- » FDA Practice Group
- » Intellectual Property Counseling
- » Intellectual Property Due Diligence
- » Intellectual Property Procurement
- » Patent Litigation
- » Trade Secret, Trademark, Trade Dress & Copyright Litigation

Attorney Contacts

- » Lauren S. Albert
- » Matthew J. Becker
- » Michael D. Bednarek
- » Michael A. Davitz, M.D.
- » Nicholas E.O. Gaglio
- » Jonathan A. Harris
- » Chad A. Landmon
- » Jeremy C. Lowe
- » Edward M. Mathias
- » Francis H. Morrison III

Speaking Engagements & Seminars

- » CBI's 4th Annual Bio/Pharmaceutical Drug Safety Forum
- » University of Connecticut, School of Law, Adjunct Professor in Patent Litigation, Spring 2012

Intellectual Property

AVH offers clients a full range of legal services in intellectual property law. While the firm focuses on patent litigation in a variety of industries, we also provide counseling and other litigation services regarding trade secrets, trademarks and copyrights. The firm represents clients seeking to enforce intellectual property rights and to avoid and defend against charges of infringement and misappropriation.

Many firms have an intellectual property practice, but AVH has earned a reputation over time as the go-to firm for high-profile matters of strategic importance. The firm has been asked to serve as lead trial counsel in the midst of or after the close of discovery of numerous occasions. Our attorneys are uniquely suited to assist clients in intellectual property matters. Not only do we possess extensive patent and technical experience, but we are also seasoned litigators and trial attorneys.

Our attorneys endeavor to link business, law and science. This ability means that we understand the particular business goals of our clients, the nuances of the law and the strategies needed to exploit the technical subject matter at issue.

News & Developments

- » AVH Represented Canadian Toy Maker Mega Brands Inc. in a Lawsuit Against Lego Group
- » AVH Assisted Actavis in Resolving Ten-Year-Old Dispute with Pfizer
- » AVH Successful in Protecting Client Alvogen's Entry to Drug Market
- » Michael Bednarek Discusses Factors Reshaping In-house Patent Strategies With Inside-Counsel
- » AVH Partners Named Connecticut Rising Stars 2011/2012

Intellectual Property (continued)

- » ACI's FDA Boot Camp: Bioequivalence - What Patent Lawyers Need to Know
- » Michael Bednarek Discusses Factors Reshaping In-house Patent Strategies
- » ACI's FDA Boot Camp Post-Conference Workshop: Non-Patent Marketing Exclusivities: Challenges, Opportunities and Current Controversies
- » "Patent Due Diligence - A Good Business Practice"
- » "How the Dynamics of Biosimilars Are Changing the Hatch-Waxman Landscape"
- » Jonathan Harris Leads Seminar Entitled, "Prior Art and Obviousness 2011: Current Trends in Sections 102 & 103"
- » AIPLA Mid-Winter Institute, meeting of the Special Committee on the FDA: Discussion of the FDA Hearings on the Biologics Price Competition and Innovation Act
- » "Paragraph IV Disputes and Litigation." ACI Hatch-Waxman Boot Camp (2011)
- » "Biosimilars and Biointerchangeables," Hatch-Waxman Boot Camp, American
- » AVH Partners Named Connecticut Super Lawyers 2011/2012
- » AVH Partners Named to Super Lawyers Business Edition 2011
- » AVH Partner Chad Landmon Honored as Hartford Business Journal "40 Under 40" Winner
- » AVH Partner Jonathan Harris Speaks with the Hartford Business Journal about Small Green Firm Winning Patent
- » AVH Partner, Associate Pen Article on Biosimilar Approval Standards Under BPCI
- » On March 17, 2011, Chad Landmon Discussed Bioequivalence at ACI's FDA Boot Camp
- » AVH Enhances IP Group with Addition of Michael Bednarek to Washington, D.C. Office
- » On February 3, 2011, Chad Landmon Presented on the FDA Hearings on the BPCI Act at the AIPLA Mid-Winter Institute
- » Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson's Abiraterone Drug For Prostate Cancer
- » AVH Attorneys Named Connecticut Super Lawyers 2011
- » On September 28, 2010, Chad Landmon Presented on Bioequivalence in Boston
- » On August 25-26, Jonathan Harris Presents on Follow-on Biologics in San Francisco
- » AVH Partner Chad Landmon Speaks with Pharmawire about Johnson & Johnson Facing Further Regulatory Scrutiny
- » AVH's Landmon Quoted by The Pink Sheet Discussing the Lovenox Lawsuit
- » AVH Attorney Named to Super Lawyers Corporate Counsel Edition July/August 2010
- » On July 19-20, Jonathan Harris Presents on Follow-on Biologics in Boston

continued

Intellectual Property (continued)

- Conference Institute
- » "Inventorship & Priority of Invention," Prior Art and Obviousness: Current Trends in Sections 102 and 103, Practicing Law Institute
- » "Pre-Trial Tactics for Brands and Generics." ACI Paragraph IV Disputes Conference (2010)
- » ACI's Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation
- » CBI's Pharmaceutical Congress on Paragraph IV Disputes and Settlements: Workshop Leader on Assessing Paragraph IV Litigation Strategies
- » "Medical Process Claims after Bilski and Prometheus," Maximizing Pharmaceutical Patent Life Cycles, American Conference Institute
- » "Patent Litigation Strategies for Follow-on Biologics," Generic Pharmaceutical Association GphA Annual Meeting
- » "Bioequivalence in Paragraph IV Patent Infringement Litigation," FDA Boot Camp, American Conference Institute
- » Assessing the Patent and FDA Strategies for
 - » On July 7, 2010, Jonathan Harris Presents on Inventorship and Prior Conception in New York City
 - » On June 3, 2010, Jonathan Harris Speaks on In Re Rosuvastatin Litigation
 - » Landmon Quoted by Pharmawire on the Possibility of a Cephalon Settlement
 - » Landmon Provides Insights on Generics Challenge of AstraZeneca's Crestor Patents to Pharmawire
 - » Landmon Discusses Teva's Launch of Generic Cozaar/Hyzaar With Market Exclusivity with The Pink Sheet
 - » Chad Landmon Discusses a Recent U.S. Court of Appeals Ruling with The Pink Sheet
 - » AVH Wins Summary Judgment on Behalf of Mutual Pharmaceutical Company
 - » AVH Partner Chad Landmon Discusses "pay-for-delay" Legislation in White House Health Care Plan
 - » AVH's Chad Landmon Discusses the Likelihood of the FTC Increasing Efforts to Obtain Passage of "Pay-For-Delay" Legislation with Drug Industry Daily
 - » Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily
 - » Chad Landmon Discusses Report on Generic Drug Availability with Generic Line
 - » Chad Landmon Discusses Astellas Court Loss with Generic Line
 - » Chad Landmon Discusses Cubist's Lawsuit Against Teva with Pharmawire
 - » Axinn Veltrop & Harkrider's Chad Landmon Speaks with Drug Industry Daily About the Drug Price Competition Act of 2009
 - » Chad Landmon Participates in Question and Answer Session with The National Law Journal on Follow-On Biologics

continued

Intellectual Property (continued)

- | | |
|--|--|
| <ul style="list-style-type: none"> Follow-On Biologics to Maximize Success » FDAnews Webinar: Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Success » ACI's Paragraph IV Disputes: Advanced Master Class - Obtaining Optimal Terms and Mitigating Antitrust Concerns When Settling Paragraph IV Disputes » CBI's Annual Summit on Biosimilars and Follow-On Biologics » "Developing Profits from Patent Assets." NIBA (2009) » "Intellectual Property and Ethics - Annual Review." AIPLA Annual Meeting (2009) » "Practical Guidelines for Assessing the Doctrine of Equivalence and Invalidity in Patent Opinion Writing," Pharmaceutical and Biotech Patent Opinion Writing, American Conference Institute » ACI's Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation » CBI's Pharmaceutical Congress on Paragraph IV Disputes » "The Patent Playbook." | <ul style="list-style-type: none"> » Chad Landmon Discusses Court Decision Enjoining Teva from Launching Generic Osteoporosis Drug with Generic Line » Chad Landmon Discusses Novartis' Exjade® with Pharmawire » Chad Landmon Discusses Court Rulings and Patent Law Reform with Thomson-Reuters » Chad Landmon Discusses Teva's At-Risk Launch of Generic Pulmicort with The Pink Sheet » Chad Landmon Discusses FDA's Letter Ruling Practice with The Pink Sheet » CBI's Pharmaceutical Congress on Paragraph IV Disputes -- Chad Landmon and Michael Davitz Discuss Litigation Strategies, Generic Exclusivity Forfeiture and Recent Developments in Paragraph IV Disputes » Chad Landmon Discusses Recent Declaratory Judgment Ruling with The Pink Sheet » Fed. Cir. Reins in Equitable Conduct Doctrine » Pfizer Buys More Time for Lipitor » IP Playbook Can Save Companies From 'World of Hurt' » Matt Becker participates in GC New England Roundtable on Patent Litigation » Law Article May Spark Patent Litigation Strategy » The Best and Worst Patents for Generics to Fight » Chad Landmon Discusses generic exclusivity forfeiture provisions with IP Law360 » Michael Keeley and Chad Landmon discuss FDA's recent 180-day exclusivity decisions with FDAnews » FDAnews Audioconference -- Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings » Axinn, Veltrop & Harkrider Boosts IP Practice » Firm Gears Up For High Stakes Drug Lit |
|--|--|

Intellectual Property (continued)

- | | |
|---|---|
| <p>LES International Annual Meeting (2008)</p> <p>» FDAnews
Audioconference:
Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings</p> <p>» Guest Lecturer at the University of Connecticut School of Law</p> <p>» Collaborating Attorney to the Connecticut Intellectual Property Notes</p> <p>» "Avoiding Compulsory Licenses in the Post-eBay Era." LES Spring Meeting (2007)</p> | <p>» Axinn, Veltrop & Harkrider LLP Expands Intellectual Property Practice</p> <p>» AVH Settles Lawsuit for Taro Pharmaceuticals</p> <p>» Jim Veltrop Featured in IP360</p> <p>» Michael Davitz quoted in IP Law & Business</p> <p>» Cantor Colburn's Michael Cantor plugs Jim Veltrop in IP Law 360</p> <p>» IP Litigation: Fran Morrison Comments on Qualcomm Legal Issues in Wall Street Journal and The Recorder</p> <p>» AVH Represents INEOS in U.S. Litigation</p> <p>» AVH Serving as Patent Counsel for ADHD and Pain Relief Medications</p> <p>» Axinn, Veltrop & Harkrider LLP Continues to Expand Its Intellectual Property Group</p> <p>» AVH Represents URL/Mutual Companies in Launch of Guaifenesin Products</p> <p>» AVH Defends Fila in Marshall, Texas Patent Action</p> <p>» Axinn, Veltrop & Harkrider LLP Expands Its Intellectual Property Group</p> <p>» AVH Represents Sport Brands International/FILA in Connection with Launch of Various Products</p> <p>» AVH Represents R.R. Donnelly in Patent and Antitrust Litigation</p> <p>» AVH Represents Purepac Pharmaceutical Company in Metformin Launch</p> <p>» AVH Represents Stanley Works in Patent Litigation</p> <p>» Stanley Defends Its Colors, Trade Turfs</p> <p>» AVH Defends Ryobi Technologies, Inc.</p> |
|---|---|

Articles & Newsletters

- » Formulation Patents and Dermatology and Obviousness
- » Innovative Procedures v. Premarketing Approval
- » Final Word: Advocating for Biosimilar Approval Standards under BPCI
- » Machine-Or-Transformation Test After Myriad: Implications To The Prosecution Of Process Claims, Practising Law Institute, Patent Law Practice Center, August 15, 2011
- » Heightened Standard For The Entire Market Value Rule?
- » Do You Have The Right To Sue: Understanding Contract Provisions in The Context of Litigation
- » Viewpoint: Advocating for Biosimilar Approval Standards under BPCI
- » The Challenges of FDA's Nascent Biosimilars Regime
- » Human Tissue and Stem Cell Therapies: Revolutionary New Therapies that Face Increasing FDA Scrutiny
- » Federal Preemption and Labeling: Where Product Liability Collides with FDA
- » Five Things Every Biotech Company Must Know About Biosimilars
- » Making it Easier to Win Patent Infringement Suits
- » Federal Circuit Obviousness Vs. SCOTUS Precedent
- » Authorized Generics: Consumer Friend or Foe?
- » Raising Questions About Patent Deception
- » FDA's Exclusivity Forfeiture Saga Continues
- » Ask the Expert: Caraco's Impact on Declaratory Judgment Actions
- » Ask the Expert: Impact of FDA's Exclusivity Forfeiture Rulings
- » Raising the Bar of Patentability
- » Here Comes The Tidal Wave of Generic DJ Actions
- » FDA Removes Teeth From Exclusivity Forfeiture
- » What is Patentable?
- » Supreme Court Backhands Key Federal Circuit Test
- » The Nanotech Researcher's Dilemma: Patent or Perish?
- » FTC Rules That Deception Regarding Patents During Standard Setting Process Violates Antitrust

Intellectual Property (continued)

Laws

- » Fourth Circuit Rejects Another Authorized Generics Challenge
- » On Demand: Focusing The Patent Scope
- » FDA's "Holding On The Merits" Test
- » Recent Court Rulings Indicate That Patent Rights May Trump the Antitrust Laws
- » Supreme Court Abandons Presumption of Market Power in Patent-Tying Cases
- » The "Narrowed Claim Conundrum" Resulting from Reissue and Reexamination Proceedings
- » The Impact of a Brand Generic Launch on the Recovery of Patent Damages
- » "Schering" Overruled: Risk of Settling Patent Suits Reduced?
- » Invention is the Mother of Litigation
- » Trade Secret Misappropriation A Federal Crime
- » The New European Union Technology Transfer Block Exemption